This Article Full Text Full Text (PDF) All Versions of this Article: 36/12/2660    most recent 01.STR.0000189634.08400.82v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flaherty, M. L. Articles by Broderick, J. P. Search for Related Content PubMed PubMed Citation Articles by Flaherty, M. L. Articles by Broderick, J. P. Pubmed/NCBI databases Substance via MeSH Related Collections Acute Cerebral Hemorrhage Emergency treatment of Stroke Intracerebral Hemorrhage Other Stroke Treatment - Medical Epidemiology Related Article

(Stroke. 2005;36:2660.)
© 2005 American Heart Association, Inc.

Original Contributions

Potential Applicability of Recombinant Factor VIIa for Intracerebral Hemorrhage

Matthew L. Flaherty, MD; Daniel Woo, MD, MS; Mary Haverbusch, BSN; Charles J. Moomaw, PhD; Padmini Sekar, MS; Laura Sauerbeck, RN, MS; Brett Kissela, MD; Dawn Kleindorfer, MD Joseph P. Broderick, MD

From the Departments of Neurology (M.L.F., D.W., M.H., C.J.M., L.S., B.K., D.K., J.P.B.) and Environment Health (P.S.), University of Cincinnati Medical Center, Cincinnati, OH.

Correspondence to Matthew L. Flaherty, MD, 231 Albert Sabin Way, MSB Room 5060, University of Cincinnati Medical Center, Cincinnati, OH, 45267-0525. E-mail matthew.flaherty{at}uc.edu

Background and Purpose— To date, there are no proven, effective treatments for intracerebral hemorrhage (ICH) beyond supportive medical care. A recent randomized, blinded, placebo-controlled trial of recombinant factor VIIa (rFVIIa) administered intravenously within 4 hours of ICH onset reported a reduction in morbidity and mortality compared with placebo. We sought to determine the potential applicability of rFVIIa in a large, population-based cohort of ICH patients.

Methods— All of the patients age 18 years hospitalized with nontraumatic ICH in the Greater Cincinnati region were identified from May 1998 to July 2001 and August 2002 to April 2003. Patient demographics were compared with the inclusion and exclusion criteria from the rFVIIa trial to determine eligibility for treatment and reasons for exclusion. Mortality in the eligible patient group was compared with the placebo group in the rFVIIa trial.

Results— Over 4 calendar years, 1018 ICH patients were identified; of these, 133 (13.1%) had no exclusions and presented within the prescribed time window. An additional 45 patients (4.4%) may have been eligible but had uncertain onset or computed tomography scan times. The most common reasons for exclusion (not mutually exclusive) were late presentation (n=398), vaso-occlusive disease (n=369), deep coma (n=219), and prolonged international normalized ratio or partial thromboplastin time (n=200). Mortality at 90 days among potentially eligible patients was the same as for the placebo group in the rFVIIa trial (29% versus 29%; P=0.99).

Conclusions— In this large, population-based ICH cohort, 13.1% to 17.5% of patients would have qualified for treatment with rFVIIa by trial criteria.

Key Words: intracerebral hemorrhage • epidemiology • outcome

Related Article:

From Trials to "Real Life": Necessity of Efficacy

Charlotte Cordonnier
Stroke 2005 36: 2527. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. N. Goldstein, L. E. Fazen, R. Snider, K. Schwab, S. M. Greenberg, E. E. Smith, M. H. Lev, and J. Rosand Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage Neurology, March 20, 2007; 68(12): 889 - 894. [Abstract] [Full Text] [PDF]

				C. Cordonnier From Trials to "Real Life": Necessity of Efficacy Stroke, December 1, 2005; 36(12): 2527 - 2527. [Full Text] [PDF]